Canada CAR T-Cell Therapy Market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of xx% during the forecast period (2019-2028).
For many years, the support of cancer therapy was chemotherapy, surgery, and radiation therapy. However, in recent times, CAR T-Cell therapy has been introduced as an incredibly supportive treatment for cancer patients. Since the introduction of chemotherapy, this treatment is one of the most significant breakthroughs. In this therapy, immune cells are collected from patients, and it is modified in the laboratory by doctors. After modification, these immune cells are infused back into the patient as they can easily recognize and kill cancer cells. These infused cells get multiplied and stay in the body as “living drugs.
Factors that drive the Canada CAR T-Cell therapy market are the increase in the number of cancer cases, the rising occurrence rate of haematological cancer like leukaemia, lymphoma, and multiple myeloma propelling the market growth over the forecast period. Growing investments made by the government and other private organizations are surging the T-cell therapy market growth over the analysis period. Increasing healthcare expenditure and increasing disposable income are fuelling market growth over the forecasting framework.
The cost associated with the CAR T-Cell therapy market is so expensive and is restraining the market growth to some extent over the forecast timeframe. Also, CAR T-Cell therapy can cause side effects post-therapy may also hamper the market growth during the forecast period.